SCHEDULE: BlackRock Discloses 10.1% Stake in Keros Therapeutics

BlackRock, Inc. has reported beneficial ownership of 10.1% of Keros Therapeutics, Inc.'s common stock as of March 31, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Keros Therapeutics, Inc. common stock.
• As of March 31, 2026, BlackRock beneficially owns 1,990,842 shares, representing 10.1% of the class of securities.
• This ownership includes sole voting power over 1,960,306 shares and sole dispositive power over 1,990,842 shares.
• The filing specifies that BlackRock, Inc. is the reporting person, and the securities are held in the ordinary course of business, not for the purpose of influencing control of the issuer.
• Several subsidiaries and affiliates of BlackRock, Inc. are listed as entities that may beneficially own these securities, with BlackRock Fund Advisors specifically noted as beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership and does not provide new operational or financial information about Keros Therapeutics itself.

Positives

• BlackRock, a significant institutional investor, has taken a substantial stake in Keros Therapeutics, which could be interpreted as a vote of confidence in the company's future prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a passive investment strategy rather than an attempt to gain control.

Negatives

• The filing does not contain any negative financial results or operational challenges for Keros Therapeutics; it solely reports on BlackRock's ownership stake.

Risks

• While not explicitly stated as a risk in this filing, a significant ownership stake by an institutional investor can sometimes lead to increased scrutiny and potential pressure on management regarding performance and strategy.
• The concentration of 10.1% of shares in a single entity could lead to increased volatility if BlackRock decides to significantly alter its position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Keros Therapeutics, Inc. regarding its future performance.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by major asset managers like BlackRock in biotechnology companies are common, reflecting active portfolio management and belief in the sector's growth potential. Keros Therapeutics operates in the highly competitive and capital-intensive biotechnology space, where institutional backing is crucial for funding research and development.

Stakeholder Impact

• Shareholders: The increased institutional ownership by a major player like BlackRock may be viewed positively, potentially increasing liquidity and signaling confidence, but also raises questions about future strategic direction if BlackRock becomes more active.
• Management: May face increased expectations for performance and strategic execution due to the significant stake held by BlackRock.
• Creditors/Suppliers: No direct impact indicated by this filing.

Next Steps

• Keros Therapeutics, Inc. will continue its operations and research and development activities.
• BlackRock, Inc. will continue to hold its shares and may adjust its position based on its investment strategy and market conditions.

Key Dates

Keywords

Keros Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Biotechnology